Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03A adjuvant in HIV-1-infected adults

AIDS

Volumn 27, Issue 1, 2013, Pages 87-93

  Durier, Christine ^a   Desaint, Corinne ^b   Lucht, Frédéric ^a   Girard, Pierre Marie ^c   Lévy, Yves ^d   May, Thierry ^e   Michelet, Christian ^f   Rami, Agathe ^g   Roman, François ^h   Delfraissy, Jean François ⁱ   Aboulker, Jean Pierre ^a   Launay, Odile ^b  

^a INSERM   (France)

^b Université Paris Descartes ^*  (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d INSERM U955   (France)

^e CHU NANCY BRABOIS   (France)

^f PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^g HÔPITAL LARIBOISIÈRE   (France)

^h GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

ⁱ BICÊTRE HOSPITAL   (France)

Author keywords

adjuvant; flu vaccine; HIV; immunogenicity; persistence

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS RNA;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HEMAGGLUTINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

ADJUVANTS, IMMUNOLOGIC; ALPHA-TOCOPHEROL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DRUG COMBINATIONS; FEMALE; FRANCE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS; HIV INFECTIONS; HIV-1; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SMOKING; SQUALENE; TIME FACTORS;

EID: 84871612462     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328359f27a     Document Type: Article

References (15)

1. Updated interim recommendations: HIV-infected adults and adolescents-considerations for clinicians regarding 2009 H1N1 influenza. http://www. cdc. gov/h1n1flu/guidance-hiv. htm. [Accessed 18 April 2010].
2. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9:493-504.
3. Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24:2187-2192; 8.
4. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
5. Crum-Cianflone NF, Iverson E, Defang G, Blair PJ, Eberly LE, Maguire J, et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011; 29:3183-3191.
6. Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011; 204:124-134.
7. Kendal AP, Skehel JJ, Pereira MS. Concepts and procedures for laboratory-bases influenza surveillance. Atlanta: Centers for Disease Control and Prevention; 1982. pp. B17-B35.
8. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Li P, et al. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vacc Immunother 2012; 8:260-266. http://www. landesbioscience. com/journals/13/article/18469/. [Accessed 10 September 2012].
9. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorization application (CPMP/VEG/4717/03). European Agency for the Evaluation of Medicinal Products; 2004.
10. FDA Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration; 2007. http://www. fda. gov/cber/gdlns/panfluvac. htm. [Accessed 5 February 2011].
11. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-3935.
12. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733-744.
13. Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998; 12:F217-223. (Pubitemid 28526400)
14. Calmy A, Bel M, Nguyen A, Combescure C, Delhumeau C, Meier S et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med 2012; 13:207-218.
15. Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128-137.